Growth peptides

CJC-1295 (NO DAC) + Ipamorelin

Lyophilised research vial · batch tested

AED 329

• UAE-wide delivery, 1–3 working days
• Shipped cold in insulated packaging
• COA available for every lot

For research use only. This product is not a medicine and is not intended for human or veterinary consumption, diagnostic or therapeutic use.

Description

CJC-1295 (NO DAC) + Ipamorelin is a synergistic research peptide combination that has attracted significant interest within the scientific community for its complementary interaction with growth hormone regulatory pathways. By combining CJC-1295 (NO DAC), a growth hormone-releasing hormone (GHRH) analogue, with Ipamorelin, a selective growth hormone secretagogue receptor agonist, this peptide blend is widely studied for its potential role in supporting endogenous growth hormone signalling. Researchers have explored this combination for its involvement in recovery processes, tissue regeneration, protein synthesis, body composition, and metabolic regulation. The complementary mechanisms of these two peptides distinguish this formulation from single-compound approaches, making it a prominent focus in ongoing endocrine and regenerative research. Due to its targeted interaction with growth hormone pathways, CJC-1295 (NO DAC) + Ipamorelin continues to be investigated for its potential impact on cellular repair, recovery, sleep quality models, and overall physiological function. As one of the most extensively studied peptide combinations in growth hormone research, it remains a key area of investigation for scientists exploring regeneration, metabolism, and healthy aging.

Research summary

• Supplied lyophilised in a sealed glass vial
• Identity and purity verified by HPLC and mass spectrometry
• Batch-specific certificate of analysis available on request